logo
Western Canadian glaciers melting twice as fast as they did a decade ago, research shows

Western Canadian glaciers melting twice as fast as they did a decade ago, research shows

CBC13 hours ago

Researchers say some glaciers in Western Canada and the United States lost 12 per cent of their mass from 2021 to 2024, doubling melt rates compared to the previous decade.
The research led by University of Northern British Columbia professor Brian Menounos says low snow accumulation over winter, early-season heat waves, and prolonged warm and dry spells were contributing factors.
It says impurities such as ash from severe wildfire seasons have also "darkened" glaciers, causing them to absorb more heat and triggering a feedback loop that will lead to continued loss unless the ice is covered by fresh snow.
The study, published in the peer-reviewed journal Geophysical Research Letters this week, examined glaciers in Western Canada and the United States, excluding Alaska and Yukon, as well as Switzerland, where glaciers lost 13 per cent of their mass over the same period.
The research letter says glaciers in both regions lost mass twice as fast as they did between 2010 and 2020.
"Unfortunately, in the last four years, we've seen yet another doubling of how much water we're losing from our glaciers annually," he told CBC Radio West host Sarah Penton.
To make the point, he said the annual loss is roughly equivalent to the entirety of B.C.'s Okanagan Lake — or the beds of a billion pick-up trucks.
Menounos says climate change and its effects, including heat waves and changing snow patterns, are draining the "bank account" of fresh water that glaciers contain.
"Doubling the amount of water that's lost from those glaciers, we're sort of stealing from the future," said Menounos, who is also the Canada Research Chair in glacier change.
"We are just pulling and pulling away and making that bank account closer to zero and perhaps even negative. We're not replenishing these glaciers," he said.
The research combined aerial surveys with ground-based observations of three glaciers in Western Canada, four glaciers in the United States and 20 in Switzerland.
The analysis shows that between 2021 and 2024, those glaciers experienced their highest rates of loss since monitoring began 60 years ago, Menounos says.
The research letter says that in Western Canada and the United States, black carbon doubled after about 2010, reaching the highest level of deposition in 2023 — coinciding with a severe wildfire season across B.C. and Canada.
The study did not include specific data relating to wildfire ash on each glacier, but Menounos says any darker material will absorb more heat and enhance melting.
The researchers did zero in on the Haig Glacier in the Canadian Rockies, finding the low reflectivity of the ice contributed to 17 per cent of an unprecedented loss of mass in 2022 and 2023. Summer heat had the greatest effect, responsible for 46 per cent of the loss, the letter says.
Current modelling for glaciers often doesn't include wildfire ash and other processes that could accelerate rates of loss in the future, Menounos added.
"We think that wildfire will continue to play an important role, and certainly we need better physical models to project how these glaciers are likely to change."
WATCH | How melting glaciers will impact the world's water supply:
Melting ice and glaciers could lead to water crisis
4 years ago
Duration 2:51
A new study finds that ice is disappearing around the globe at an alarming rate and glaciers represent a significant amount of ice loss. Researchers in Canada say the retreat of glaciers will have major impacts on water security in Canada.
Glaciers across the study area are projected to mostly disappear by the end of the century, even under moderate climate change scenarios. Only some of the largest glaciers and icefields are expected to exist beyond 2100, the research letter says.
Swiss glaciers represent about 55 per cent of the total volume of central European glaciers, and findings there may be applied across the Alps, the letter notes.
From 2000 to 2023, the letter says Earth's glaciers collectively lost mass at a rate of about 273 gigatonnes per year, accounting for about one-fifth of observed sea-level rise. One gigatonne represents one cubic kilometre of water.
The research letter published Wednesday follows a 2021 study published in the peer-reviewed journal Nature that found glaciers outside the Greenland and Antarctic ice sheets lost mass between 2010 and 2019 at double the rate they did in the first decade of this century. Menounos contributed to that study.
"The way to perhaps bring some of the smallest glaciers back is, sometime in the future, with reduced greenhouse gas emissions," he said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pacific Defense Secures Launch for MOSA Space RF Payload
Pacific Defense Secures Launch for MOSA Space RF Payload

National Post

time3 hours ago

  • National Post

Pacific Defense Secures Launch for MOSA Space RF Payload

Article content EL SEGUNDO, Calif. — Pacific Defense, the leading provider of Modular Open Systems Approach (MOSA) products, announced it has secured the inaugural launch for its Moonraker MOSA space Radio Frequency (RF) payload on board the K2 Space Gravitas Mission in February 2026. The mission includes a series of multi-orbit Space Situational Awareness (SSA) demonstrations showcasing the payload's mission flexibility. Article content We are taking the MOSA initiative to space with Moonraker. Article content Moonraker is a 3U Open VPX multi-function, RF payload with application software capable of performing a range of RF missions that fundamentally changes the cost, schedule, and deployment concept for responsive space missions. Designed for SSA, Moonraker payload architecture fully supports a range of receive and transmit Electromagnetic Spectrum Operation (EMSO) functions to command the electromagnetic operational environment. Article content 'We're thrilled to take the United States Department of Defense's MOSA initiative to new heights with Moonraker,' said Bryan Terlecky, Vice President of Space Systems at Pacific Defense. 'As global space competition intensifies, there is a pressing need for adaptable, software-driven solutions that can rapidly evolve to counter emerging threats. This mission marks a significant step in our commitment to providing innovative and flexible solutions for space control'. Article content The on-orbit demonstration, being completed under a contract with the Air Force Research Lab/Space Vehicles Directorate (AFRL/RV), is a critical milestone for Pacific Defense's Space MOSA payloads and will inform future operational systems. For more information, please visit Space Systems. Article content About Pacific Defense Article content Article content Article content Article content Contacts Article content Article content

AI systems may make mistakes now but are quickly getting smarter: Hinton
AI systems may make mistakes now but are quickly getting smarter: Hinton

CTV News

time3 hours ago

  • CTV News

AI systems may make mistakes now but are quickly getting smarter: Hinton

AI pioneer Geoffrey Hinton is seen backstage before speaking at the Collision Conference, in Toronto, on Wednesday, June 19, CANADIAN PRESS/Chris Young TORONTO — If mistakes artificial intelligence make have you doubting it can't ever rival humans, one of the technology's pioneers says think again. Geoffrey Hinton said Wednesday that AI keeps getting better at reasoning and has surpassed the skill level many experts expected it to be at by 2025. Yet every time the technology messes up, he said people have an itch to conclude that AI didn't understand what was being asked of it. 'There's recent research showing that you give it something easy, it probably gets it right. You give it a slightly more difficult problem, it takes longer and it still gets it right,' said the recent Nobel Prize winner. 'But if you give it a more difficult problem… and it gets it completely wrong, people use that to say, 'well it couldn't really reason at all.' The way he sees it is that AI can solve simple, immediate problems, but stumbles on anything more complicated like humans do. While improving the technology so it is not tripped up by anything complicated will be a challenge, he said it's more of a stumbling block than a hurdle that can't be overcome. And when it is overcome, he said humans have plenty to be worried about. 'We're all going to have very smart AI assistants and…. we're not going to need ordinary assistance,' he said. 'But there's also the question of whether these things, when they get smarter than us, are going to need us.' When AI becomes smarter than us, he said it would manifest as the technology coming up with schemes and doing things 'you would have never thought of them.' 'If you had an argument with them about anything, they would win the argument,' he said. While winning arguments may seem trivial, Hinton has several concerns about the technology's potential that go well beyond arguments. On top of an existential risk to humanity, he worries the technology could cause unemployment, bias and discrimination, echo chambers, fake news and autonomous lethal and biological weapons. Countering these issues will take immense public pressure to create regulations with teeth that will rein in tech companies, which he said will fight any guardrails. He likens the situation to climate change. 'Obviously, the big oil companies didn't believe in regulations, and the public needed to be convinced there was climate change, so they would apply pressure on the politicians from the other side saying do something about it,' he said. 'I think this is the same situation.' His remarks were made in a Toronto Tech Week panel with Nick Frosst, one of Hinton's proteges and a co-founder of buzzy AI firm Cohere. Their discussion was at the University of Toronto, where Hinton is a professor emeritus and Frosst was his student. They've remained close despite having diverging views on AI. For example, Hinton thinks AI poses an existential threat and Frosst isn't convinced it does. While they both agree the technology will upend the job market, they disagree about how. Frosst said the large language models (LLMs) that underpin AI systems will automate 20 to 30 per cent of everyone's jobs done while sitting in front of a computer. 'The danger is when they do 80 per cent,' Hinton said. 'I think that's where we disagree,' Frosst replied. 'I think there's a limit and I think there's lots of work that we do now as people in our jobs and at our homes and in our personal lives that an LLM will not be able to do.' Tara Deschamps, The Canadian Press

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

National Post

time4 hours ago

  • National Post

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

Article content BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Article content Promising new data from pipeline assets in breast, lung, and GI cancer franchises, including CDK4 inhibitor, B7-H4 ADC, and novel PRMT5 inhibitor, will be featured Article content Pipeline is at an exciting inflection point with 20 near-term milestones in the next 18 months Article content SAN CARLOS, Calif. — In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today's investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition. 'At BeOne, our mission is simple yet bold: to create the world's first next-generation oncology company,' said John V. Oyler, Co-Founder, Chairman, and CEO. 'What we will unveil demonstrates our progress towards this goal today, and the promise for tomorrow. From our innovative discovery engine to one of the broadest pipelines in oncology, we are well-positioned to bring transformative medicines to patients worldwide—and to do so with speed, quality, and purpose.' Article content BeOne's integrated, end-to-end R&D model is engineered for efficiency without compromise. The Company's differentiated approach—combining in-house discovery targeting unmet patient needs, parallel early-stage exploration at low incremental cost, and rapid proof-of-concept generation—enables swift progression from bench to clinic. Our in-house manufacturing around the world, including our flagship facility in Hopewell, NJ, means we have a sustainable business model, purpose built with competitive advantages. This rigorous model has fueled a pipeline of more than 40 clinical and commercial-stage assets, making it one of the most productive in the industry. To complement this research engine, BeOne has built a robust global clinical development platform, with more than 170 trials conducted across 40 countries and more than 25,000 patients enrolled to date. Article content In hematologic cancers, the Company's program is driven by its wholly-owned assets including BRUKINSA ® (zanubrutinib), a second-generation covalent BTK inhibitor and the backbone of the hematology franchise, sonrotoclax, a potential best-in-class next-generation BCL2 inhibitor, and BGB-16673, a BTK CDAC. New clinical data from CaDAnCe-101 highlight the promise of BGB-16673, a potential first-in-class BTK degrader, for patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL). Meanwhile, early data show the combination of sonrotoclax and BRUKINSA has demonstrated compelling efficacy and the potential to offer a best-in-class fixed-duration treatment in CLL, setting the stage for a possible new standard of care. Article content In solid tumors, the Company is advancing multiple targeted modalities beyond its foundational PD-1 inhibitor TEVIMBRA ® (tislelizumab-jsgr), including CDK4 inhibitor BGB-43395, which has shown clear pharmacodynamic activity and is expected to enter registration-enabling studies for the treatment of breast cancer within the next six to 12 months. Article content Promising new data for the B7-H4 ADC (BG-C9074) point to a potential first-in-class therapeutic option for patients with B7-H4 expressing tumors, including those without selection criteria. Additionally, early data from the novel PRMT5 inhibitor suggest a favorable safety profile and promising efficacy, supporting its potential for differentiation in the competitive lung cancer field. Article content 'Our R&D team is running at full speed,' said Lai Wang, Ph.D., Global Head of R&D. 'With more than 1,200 scientists and more than 3,700 clinical development and medical affairs colleagues dedicated to pushing the boundaries of oncology, we have built the infrastructure, mindset, and capabilities to deliver sustained innovation. The volume of clinical milestones we anticipate over the next few years is extraordinary, and our agility in moving from idea to execution sets us apart.' Article content Speakers at today's event include BeOne's executive leadership team, senior R&D leaders, and distinguished key opinion leaders, offering a multi-faceted view of the Company's scientific strategy and execution momentum. The live webcast begins at 8:30 a.m. U.S. Eastern Time and is available on the investor relations section of BeOne's website, where an archived version will also be accessible. Article content About BeOne Article content BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the future success of BeOne's pipeline assets; BeOne's ability to bring transformative medicines to patients worldwide with both speed and quality; the productivity of BeOne's pipeline; the ability of BeOne's assets to provide a new standard of care; the timing for BGB-43395 to enter registration-enabling studies; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. Article content Article content Article content Article content Article content Contacts Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store